Compare Annaly Capital Management, Inc. (NLY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Smith & Nephew plc — how do they compare? Annaly Capital Management, Inc. trades at $18.3 (market cap $13.77B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Annaly Capital Management, Inc. is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.42%). Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 91 Days and Smith & Nephew plc for 121 Days on average.
| NLY | SNN | |
|---|---|---|
Market Cap | $13.77B | $11.10B |
Volume | 21,283,879 | 1,051,703 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $37.17 |
52-Week Low | $17.93 | $26.42 |
Typical Hold Time | 91 Days | 121 Days |
Enterprise Value | $135.80B | $14.13B |
Dividend Yield | 16.42% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.27, up 1.9% with strong earnings momentum after beating estimates for three consecutive quarters. The stock offers a compelling 16.4% dividend yield with a recent increase to $0.75 per share. Valuation appears attractive with a P/E of 4.41 and P/B of 0.91, though technical indicators show bearish momentum. The company has demonstrated portfolio expansion from $73B in 2023 to $107B in 2026, driving earnings growth.
NLY presents a high-yield opportunity with discounted valuation and consistent earnings beats, but faces interest rate sensitivity and technical headwinds. The 57% analyst buy rating and $22 consensus target suggest 20% upside potential, though investors must weigh the attractive yield against mortgage REIT volatility and recent price weakness.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
